Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
291.04
+1.89 (0.65%)
Aug 13, 2025, 4:00 PM - Market closed
Cencora Revenue
Cencora had revenue of $80.66B in the quarter ending June 30, 2025, with 8.65% growth. This brings the company's revenue in the last twelve months to $316.65B, up 11.56% year-over-year. In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth.
Revenue (ttm)
$316.65B
Revenue Growth
+11.56%
P/S Ratio
0.18
Revenue / Employee
$6,883,791
Employees
46,000
Market Cap
56.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
COR News
- 1 day ago - Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap - Seeking Alpha
- 5 days ago - Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy - Seeking Alpha
- 7 days ago - Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Cencora raises annual profit forecast on strong demand for specialty drugs - Reuters
- 8 days ago - Cencora Reports Fiscal 2025 Third Quarter Results - Business Wire
- 6 weeks ago - Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release - Business Wire
- 2 months ago - Cencora Elects Lori J. Ryerkerk to Its Board of Directors - Business Wire
- 3 months ago - Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs - Seeking Alpha